In Brief: Psivida, Compumedics, Avantogen
Wednesday, 22 June, 2005
Psivida (ASX:PSD) has released the full results of its Phase IIa trial of BrachySil in inoperable primary liver cancer patients, showing that the product is safe and effective in prompting tumour regression.
Compumedics (ASX:CMP) has promoted Dr Curtis Ponton to vice president and chief scientist for the Compumedics Neuroscan business group following the departure of Dr Stephen Sands.
Paul Hopper, who resigned as CEO and managing director of Australian Cancer Technologies (ASX:ACU) -- now known as Avantogen -- in February, has been appointed chairman of US based biotech Innovate Oncology (OTC:IOVO), a company founded by Bioaccelerate Holdings (OTC:BACLE). Innovate Oncology owns the North American rights, with Avantogen, to RP-101, a pancreatic cancer drug currently in Phase II clinical studies.
Farm animals and aquaculture cryopreservation partnership announced
Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
